Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 8:01 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,145 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Preventive Measures Clear all
Recruiting Phase 3 Interventional

Kidney Transplant Preemptive Therapy or Prophylaxis for CMV Prevention in D+R Recipients

NCT06798909
View directory record Official record
Conditions
Cytomegalovirus (CMV), Kidney Transplant; Complications, Kidney Diseases
Interventions
Valganciclovir (Pre-emptive CMV Therapy), Valganciclovir CMV Prophylaxis
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
8
States / cities
San Francisco, California • Miami, Florida • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 28, 2026, 8:01 PM EDT
Recruiting Phase 3 Interventional

A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A

NCT07416604
View directory record Official record
Conditions
Hemophilia A
Interventions
NXT007, Emicizumab
Combination Product · Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
12 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
10
States / cities
Orange, California • Aurora, Colorado • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 28, 2026, 8:01 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Socio-Structural Intervention to Improve Pre-Exposure Prophylaxis Services for Cisgender Women

NCT07318532
View directory record Official record
Conditions
HIV Prevention Program
Interventions
The women's PrEP Project (W-PrEP)
Behavioral
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
Female only
Enrollment
745 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Oct 28, 2026, 8:01 PM EDT
Withdrawn Phase 4 Interventional

Comparison Study of Cefazolin Versus Cefazolin Plus Azithromycin Prophylaxis in Post-Cesarean Endometritis

NCT01721616
View directory record Official record
Conditions
Endometritis
Interventions
Azithromycin, Cefazolin
Drug
Lead sponsor
University of Missouri, Kansas City
Other
Eligibility
Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated May 5, 2015 · Synced Oct 28, 2026, 8:01 PM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers Results available

Pre-Exposure Prophylaxis Study of Lenacapavir in Cisgender Men, Transgender Women, Transgender Men, and Gender Nonbinary People at Risk for HIV Infection

NCT04925752
View directory record Official record
Conditions
Pre-Exposure Prophylaxis of HIV Infection
Interventions
Oral Lenacapavir (LEN), F/TDF, Sub-cutaneous (SC) Lenacapavir (LEN), Placebo SC LEN, PTM F/TDF, PTM Oral LEN, F/TAF (for US participants only)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
16 Years and older
Enrollment
3,292 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2028
U.S. locations
60
States / cities
Birmingham, Alabama • Loma Linda, California • Los Angeles, California + 43 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 28, 2026, 8:01 PM EDT
Completed Phase 3 Interventional Results available

rVWF IN PROPHYLAXIS

NCT02973087
View directory record Official record
Conditions
Von Willebrand Disease
Interventions
von Willebrand factor (Recombinant), Antihemophilic Factor (Recombinant)
Biological
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
8
States / cities
Loveland, Colorado • Gainesville, Florida • Jacksonville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2021 · Synced Oct 28, 2026, 8:01 PM EDT
Completed Not applicable Interventional

A Study of Nystatin in the Prevention of Fungal Infections of the Mouth in Patients With AIDS or AIDS-Related Syndromes

NCT00002293
View directory record Official record
Conditions
Candidiasis, Oral, HIV Infections
Interventions
Nystatin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
12 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
Birmingham, Alabama • Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 2, 2007 · Synced Oct 28, 2026, 8:01 PM EDT
Completed Not applicable Interventional

A Study of Azithromycin in the Prevention of Mycobacterium Avium Complex Disease (MAC) in HIV-Infected Patients

NCT00002309
View directory record Official record
Conditions
Mycobacterium Avium-Intracellulare Infection, HIV Infections
Interventions
Azithromycin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
3
States / cities
San Diego, California • Fort Bragg, North Carolina • Lackland Air Force Base, Texas
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 28, 2026, 8:01 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Mitoquinone/Mitoquinol Mesylate as Oral and Safe Postexposure Prophylaxis for Covid-19

NCT05886816
View directory record Official record
Conditions
SARS-CoV Infection, COVID-19
Interventions
Mitoquinone/mitoquinol mesylate, Placebo
Drug · Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
122 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 28, 2026, 8:01 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Uterotonic Prophylaxis Trial

NCT02408965
View directory record Official record
Conditions
Hemorrhage
Interventions
Methergine, placebo
Drug · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Female only
Enrollment
284 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 6, 2019 · Synced Oct 28, 2026, 8:01 PM EDT
Terminated Phase 4 Interventional Results available

Seizure Prophylaxis in Aneurysm Repair

NCT01974700
View directory record Official record
Conditions
Intracranial Aneurysms, Seizures
Interventions
Levetiracetam
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 11, 2016 · Synced Oct 28, 2026, 8:01 PM EDT
Recruiting Phase 2 Interventional

Allogeneic HSCT With Low-Dose Post-Transplant Cyclophosphamide for GVHD Prevention

NCT06926595
View directory record Official record
Conditions
Graft-versus-Host Disease (GVHD), Hematologic Malignancies, Allogeneic Stem Cell Transplantation
Interventions
Cyclophosphamide (primary intervention for GVHD prophylaxis)
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 28, 2026, 8:01 PM EDT
Completed Phase 4 Interventional Results available

Prophylactic Antimicrobial Catheter Lock

NCT00571259
View directory record Official record
Conditions
Bacteremia
Interventions
Heparin 1000U/mL, 4% Sodium Citrate with Gentamicin 320 mcg/mL
Drug
Lead sponsor
Satellite Healthcare
Other
Eligibility
Not listed
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
Mountain View, California
Source: ClinicalTrials.gov public record
Updated Sep 22, 2021 · Synced Oct 28, 2026, 8:01 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetics and Safety of Cefazolin 3gm DUPLEX in Adults

NCT05205486
View directory record Official record
Conditions
Infections
Interventions
Cefazolin 3gm for Injection USP and Dextrose Injection USP
Drug
Lead sponsor
B. Braun Medical Inc.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
2
States / cities
Columbus, Georgia • Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Feb 28, 2025 · Synced Oct 28, 2026, 8:01 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Adapting a Behavioral Intervention to Accommodate Cognitive Dysfunction in People Who Inject Drugs

NCT05912374
View directory record Official record
Conditions
Cognitive Dysfunction
Interventions
standard Community-Friendly Health Recovery Program- Biobehavioral (CHRP-BB), enhanced Community-Friendly Health Recovery Program- Biobehavioral (CHRP-BB)
Behavioral
Lead sponsor
University of Connecticut
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 28, 2026, 8:01 PM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)

NCT07044297
View directory record Official record
Conditions
Human Immunodeficiency Virus (HIV), HIV Pre-Exposure Prophylaxis
Interventions
MK-8527, FTC/TDF, Placebo to MK-8527, Placebo to FTC/TDF
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
16 Years and older
Enrollment
4,390 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
23
States / cities
Birmingham, Alabama • Mobile, Alabama • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 28, 2026, 8:01 PM EDT
Completed Phase 3 Interventional Results available

Atogepant for Prophylaxis of Migraine in Participants Who Failed Previous Oral Prophylactic Treatments.

NCT04740827
View directory record Official record
Conditions
Episodic Migraine
Interventions
Atogepant 60 mg, Placebo
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 80 Years
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
26
States / cities
Colton, California • Encino, California • Los Alamitos, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 28, 2026, 8:01 PM EDT
Recruiting Phase 2 Interventional

Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma

NCT05972135
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Teclistamab, Talquetamab, Tocilizumab, Oral Dexamethasone
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
17
States / cities
Tucson, Arizona • Denver, Colorado • Newark, Delaware + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 28, 2026, 8:01 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Pre-Exposure Prophylaxis and Timed Intercourse for HIV-Discordant Couples

NCT02572505
View directory record Official record
Conditions
HIV, Infertility
Interventions
Truvada
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years to 40 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 6, 2017 · Synced Oct 28, 2026, 8:01 PM EDT
Not yet recruiting Phase 2 Interventional

Low Dose Dexamethasone for the Prevention of Cytokine Release Syndrome Associated With Tebentafusp

NCT07803562
View directory record Official record
Conditions
Uveal Melanoma, Metastatic
Interventions
Dexamethasone
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 28, 2026, 8:01 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Social Media Support and Financial Incentives on PrEP Adherence

NCT03078153
View directory record Official record
Conditions
Pre-Exposure Prophylaxis
Interventions
Financial Incentive, Social Media Group
Behavioral
Lead sponsor
George Washington University
Other
Eligibility
18 Years to 24 Years · Male only
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Feb 2, 2021 · Synced Oct 28, 2026, 8:01 PM EDT
Terminated No phase listed Observational

A Comparison of Extended Versus Conventional Duration of Enoxaparin Prophylaxis (i.e., Preventive Treatment) for Venous Thromboembolism (VTE, i.e., Blood Clots in the Veins) and Bleeding Event Risk in a Population With Acute Medical Illness

NCT05819112
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Not listed
Lead sponsor
Sanofi
Industry
Eligibility
40 Years and older
Enrollment
14,799 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Oct 28, 2026, 8:01 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Acceptability of Q GRFT Nasal Spray for COVID-19 Prophylaxis

NCT05180500
View directory record Official record
Conditions
COVID-19, Pharmacokinetics, Safety
Interventions
Q-Griffithsin, Placebo
Drug
Lead sponsor
Sharon Hillier
Other
Eligibility
18 Years to 55 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Oct 28, 2026, 8:01 PM EDT
Completed No phase listed Observational

VTE Prophylaxis Guidelines in Hospitalized Elders

NCT03025100
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
60 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Oct 28, 2026, 8:01 PM EDT